Advertisement

Picture EBD Group BioPharm America 2018 Boston Speakers 600x60px
Document › Details

Redx Pharma plc. (1/22/18). "Press Release: Redx Pharma Appoints Chief Medical Officer Who Will Oversee Launch of Phase I Clinical Trial of New Cancer Drug".

Organisations Organisation Redx Pharma plc (AIM: REDX)
  Group Redx Pharma (Group)
  Organisation 2 Lytix Biopharma AS
Products Product RXC004 (Redx Pharma)
  Product 2 clinical research
Persons Person Saunders, Andrew (Redx Pharma 201801– CMO before Lytix Biopharma + Linden Oncology Ltd + Eli Lilly + Roche)
  Person 2 Ross, Iain (201704 Board Member at several UK firms before Silence Therapeutics + Allergy Therapeutics + Quadrant)
     


Redx Pharma Plc (LON:REDX) has appointed a chief medical officer ahead of the imminent launch of phase I clinical trials of its lead drug.

Dr Andrew Saunders has 25 years in the cancer field and was recruited from Lytix Biopharma, a Norwegian immuno-oncology firm, where he held the same role.

He will work with the research and development team at Redx, "fronting" the clinical development of RXC004.

This is a potentially potent small molecule drug called a porcupine inhibitor that targets Wnt pathway.

Chairman Iain Ross said he was "very pleased" to announce Saunders' appointment.

"He brings to the company a wealth of relevant experience and expertise in the clinical development of oncology drugs," Ross explained.

"This will be invaluable as the company transforms into a clinical stage company with the anticipated commencement of the first phase I study on lead compound RXC004 in the coming weeks.

"We are very excited by the potential of RXC004 to make a major difference in cancer treatment.

"We intend to progress RXC004 in the clinic both as a monotherapy and in combination with a checkpoint inhibitor. Therefore, we envisage that Andrew's recent experience in immuno-oncology combination trials will be particularly pertinent to the design and execution of future clinical trials with RXC004."

Porcupine inhibitors such as RXC004 are a new and potentially breakthrough method of fighting the killer disease.

They work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness. Kill the stem cells and you have a chance of eradicating the disease completely.

Clinical trials of the new Redx drug commence in the "coming weeks".

   
Record changed: 2018-02-01

Advertisement

Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px

More documents for Redx Pharma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2018 Boston Partnering 560x80px




» top